Table 1 Summary table on vaccine assumptions
From: Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
Vaccine assumptions (proportion of exposed people avoiding the infection) | HPV 16 | HPV 18 | HPV 31, 33, 45, 52 and 58 |
|---|---|---|---|
Cervical cancer | |||
Vaccine efficacy for preventing cervical HPV16/18/31/33/45/52/58 infections | |||
 Male* | 0.411 | 0.621 | 0.411 |
 Female** | 0.76 | 0.963 | 0.76 |
Degree of protection of the vaccine against cervical HPV16/18 infections becoming persistent | 0.988 | 0.984 | 0.988 |
Degree of protection of the vaccine against HPV16/18 -related CIN | 0.979 | 1 | 0.979 |
Vaginal and vulvar cancers | |||
Vaccine efficacy for preventing vaginal/vulvar HPV16/18 infections | |||
 Male* | 0.411 | 0.621 |  |
 Female** | 0.76 | 0.963 |  |
Degree of protection of the vaccine against vaginal/vulvar HPV16/18 infections becoming persistent | 0.988 | 0.984 | Â |
Degree of protection of the vaccine against HPV16/18-related/VaIN/VIN | 1 | 1 | Â |
Anal cancers | |||
Vaccine efficacy for preventing anal HPV16/18 infections | |||
 Male* | 0.411 | 0.621 | 0.621 |
 Female** | 0.76 | 0.963 | 0.963 |
Degree of protection of the vaccine against anal HPV16/18 infections becoming persistent | |||
 Male* | 0.787 | 0.96 | 0.96 |
 Female** | 0.988 | 0.984 | 0.984 |
Degree of protection of the vaccine against HPV16/18 -related AIN | 0 | 0 | 0 |
Penile and H&N cancers | |||
Vaccine efficacy for preventing anal/penile**/H&N HPV16/18 infections | |||
 Male* | 0.411 | 0.621 |  |
 Female** | 0.76 | 0.963 |  |
Degree of protection of the vaccine against anal/penile/H&N HPV16/18 infections becoming persistent | |||
 Male* | 0.787 | 0.96 |  |
 Female** | 0.988 | 0.984 |  |
Degree of protection of the vaccine against HPV16/18 -related AIN/PIN/H&N neoplasia | 0 | 0 | Â |